Lamellasome technology has the potential to create a wide range of transformative therapeutics and medical devices. In terms of pipeline, IPF Lamellasome is our lead therapeutic. It treats idiopathic pulmonary fibrosis (IPF) and is positioned to deliver clinical data within 30 months. Our first medical device is at a stage where it will be able to demonstrate early market share in 24 months.
Lamellar’s pipeline is targeted at addressing complex and rare respiratory diseases through two platforms:
LAMELLASOME™ lead therapies, use the unique biophysical properties of LAMELLASOME™ formulations to protect lung tissues in conditions such as Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis (CF). The lead products are IPF-Lamellasome, a potential first line therapy for the treatment of IPF, and Muco-ease, a disease modifying, mucociliary clearance therapy in CF. The LAMELLASOME™ lead therapies are ready to move into the clinic in a Phase I study covering the nebulised pulmonary LAMELLASOME™ platform.
LAMELLASOME™ gene therapy platform, which use Lamellar’s proprietary Nucleic Acid Transfer (NAT) technology to assist in the intracellular delivery of a broad range of genetic material for the treatment of pulmonary diseases. This potential is demonstrated by two products: LAMELLASOME™ CF-NA for Cystic Fibrosis, and LAMELLASOME™ IPF-NA for Idiopathic Pulmonary Fibrosis.